<scp>First‐in‐human</scp> study of <scp>JNJ</scp>‐63709178, a <scp>CD123</scp>/<scp>CD3</scp> targeting antibody, in relapsed/refractory acute myeloid leukemiaMichael Boyiadzis, Juan Manuel Alonso‐Domínguez, Pinkal Desai et al.|Clinical and Translational Science|2022Cited by 35
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterationsHartmut Döhner, Andrew H. Wei, Alicia J. Allred et al.|Blood|2025Cited by 10
Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterationsJenny O’Nions, Sylvain Garciaz, Andrew H. Wei et al.|Blood|2025Cited by 4